A growing body of evidence has pointed to a role of environmental chemical exposures in breast cancer etiology. This study was to examine the association between exposure to the endocrine-disrupting metals, including cadmium (Cd), lead (Pb), and mercury (Hg), and breast cancer in US women. A nationally representative subsample of 9260 women aged ≥ 20 years in the 2003-2012 National Health and Nutrition Examination Survey was analyzed for the association of blood levels of these metals with prevalent breast cancer using multivariate logistic regression models. Of the study participants, 284 women (weighted prevalence, 2.8%) were self-reported being diagnosed with breast cancer during 2003-2012. Breast cancer women showed significantly elevated blood levels of Cd and Pb, but not Hg. After adjusting for potential confounders, we found that women in all of the higher quartiles of blood lead levels (BLLs) had significantly increased odds ratio of prevalent breast cancer compared with those in the lowest quartile. However, a significant association with prevalent breast cancer was not seen with blood levels of either Cd or Hg. Our study demonstrates a potential relationship between lead exposure, measured as BLLs, and female breast cancer. Additional epidemiologic and mechanistic studies would further explore these interactions and elucidate the potential role of lead exposure in breast cancer etiology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12032-019-1328-3 | DOI Listing |
Front Biosci (Landmark Ed)
January 2025
Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Background: Thyroid Hormones (THs) critically impact human cancer. Although endowed with both tumor-promoting and inhibiting effects in different cancer types, excess of THs has been linked to enhanced tumor growth and progression. Breast cancer depends on the interaction between bulk tumor cells and the surrounding microenvironment in which mesenchymal stem cells (MSCs) exert powerful pro-tumorigenic activities.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
Department of Chemoradiotherapy, Ningbo No 2 Hospital, 315000 Ningbo, Zhejiang, China.
Background: Breast cancer stem cells (BCSCs) are instrumental in treatment resistance, recurrence, and metastasis. The development of breast cancer and radiation sensitivity is intimately pertinent to long non-coding RNA (lncRNA). This work is formulated to investigate how the lncRNA affects the stemness and radioresistance of BCSCs.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
January 2025
Department of Hepatobiliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, China.
Since the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely related to the development, metastasis, migration, and drug resistance of malignant tumors.
View Article and Find Full Text PDFJ Biomol Struct Dyn
January 2025
Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Tryptophan catabolism is a central pathway in many cancers, serving to sustain an immunosuppressive microenvironment. The key enzymes involved in this tryptophan metabolism such as indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are reported as promising novel targets in cancer immunotherapy. IDO1 and TDO overexpression in TNBC cells promote resistance to cell death, proliferation, invasion, and metastasis.
View Article and Find Full Text PDFInt J Cancer
January 2025
Inequalities in Cancer Outcomes Network (ICON) group, Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
We aimed to investigate socio-economic inequalities in second primary cancer (SPC) incidence among breast cancer survivors. Using Data from cancer registries in England, we included all women diagnosed with a first primary breast cancer (PBC) between 2000 and 2018 and aged between 18 and 99 years and followed them up from 6 months after the PBC diagnosis until a SPC event, death, or right censoring, whichever came first. We used flexible parametric survival models adjusting for age and year of PBC diagnosis, ethnicity, PBC tumour stage, comorbidity, and PBC treatments to model the cause-specific hazards of SPC incidence and death according to income deprivation, and then estimated standardised cumulative incidences of SPC by deprivation, taking death as the competing event.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!